Résumé
Une étude rétrospective a été effectuée chez 1048 malades souffrant de douleurs dues à un cancer avancé et ayant reçu au moins trois semaines de traitement de morphine HCI per os.
Les auteurs ont divisé cette population en fonction des différentes pathologies oncologiques et des localisations métastatiques éventuelles responsables de la symptomatologie douloureuse, ceci afin de pouvoir évaleur l’efficacité analgésique de la morphine orale.
Au niveau des résultats, la population a été subdivisée en deux groupes de malades: ceux dont la douleur était suffisamment soulagée («douleur soulagée») et ceux dont la douleur n’a pas été soulagée («douleur non soulagée»). Les effets secondaires et les doses de morphine administrées chez les deux groupes ont été ensuite analysés. Il en est résulté que les pathologies «tête et cou» et «autres» répondent au traitement par voie orale d’une façon plus significative que les autres pathologies et, que les malades atteints d’une «douleur non soulagée», malgré l’administration d’une dose considérablement plus forte de morphine, présentaient un nombre d’effets secondaires de signification statistique plus élevée.
Summary
In a retrospective analysis, 1048 patients affected by advanced cancer pain, who had been treated with morphine chlorhydrate for at least three weeks, were investigated.
The authors of this study divided the specimen according to the patient’s type of cancer and to possible metastatic sites responsible for pain. This subdivision aimed at assessing the analgesic effectiveness of oral morphine with regard to different cancer types. A division was finally carried out between patients with relieved and patients with unrelieved pain. Side-effects and morphine dosages were also analysed in both groups. As a result, «head & neck» and «other» painful pathologies appeared to be significantly more responsive than other pathologies to oral treatment and that the incidence of side-effects was significantly higher in patients with unrelieved pain, even though they were receiving significantly larger doses of morphine.
This is a preview of subscription content, log in via an institution to check access.
Bibliographie
Arner S. andArner B.: Differential effect of epidural morphine in the treatment of cancer related pain.Acta Anaesth. Scand. 29, 32, 1985.
Bonica J.J.: Treatment of cancer pain: current status and future needs.In:Advances in Pain Research and Therapy. Eds: Fields M.L., Dubner F., Cervero F. Vol. 9, Raven Press, New York, p. 589–616, 1985.
Dickson R.J. andRussell P.S.B.: Pain unresponsive to high dose opiate drugs.Palliative Medicine 3, 61–64, 1989.
Foley K.M.: The treatment of cancer pain.N. Engl. J. Med. 313, 84–95, 1985.
Goldberg R.J., Mor V., Wiemann M., Greer D.S. andHiris J.: Analgesic use in terminal cancer patients: report from the National Hospice Study.J. Chron. Dis. 39, 37–45, 1986.
Gray G., Adler D., Fleming C. andBrescia F.: A clinical data base for advanced cancer patients. Implications for nursing.Cancer nursing 11 (2), 77–83, 1988.
Henriquet F., Grasso M.A., Baldini C. eMaurelli A.: Il trattamento del dolore oncologico nell’ambito di un ospedale generale. Casistica Clinica.Algologia 2, 107–122, 1984.
Higginson I. andMcCarthy M.: Measuring symptoms in terminal cancer: are pain and dyspnoea controlled?Journal of the Royal Society of Medicine 82, 264–267, 1989.
Norton W.S. andLack S.A.: Control of symptoms other than pain.In:The Continuing Care of Terminal Cancer Patients. Eds: Twycross R.G. and Ventafridda V., Pergamon Press, Oxford, p. 167–178, 1980.
Payne R.: Anatomy, Physiology and Pharmacology.Cancer Suppl. 63, 2266–2274, 1989.
Takeda F.: Preliminary report from Japan on results of field, testing of WHO Draft interim guidelines for relief of cancer pain.The Pain Clin. J. 1, 83–89, 1986.
Tamburini M., Selmi S., De Conno F. andVentafridda V.: Semantic descriptors of pain.Pain 25, 187–193, 1987.
Twycross R.G.: Ethical and clinical aspects of pain treatment in cancer patients.Acta Anaesth. Scand. Suppl. 74, 83–90, 1982.
Twycross R.G. andLack S.A.:Symptom control in far advanced cancer: pain relief. Pitman, London, 1983.
Ventafridda V., Saita L., Ripamonti C. andDe Conno F.: WHO guidelines for the use of analgesics in cancer pain.Int. J. Tiss. Reac. 7 (1), 93–96, 1985.
Ventafridda V., Tamburini M., Caraceni A., De Conno F. andNaldi F.: A validation study of the WHO method for cancer pain relief.Cancer 59, 850–856, 1987.
Ventafridda V., De Conno F., Di Trapani P., Gallico S., Guarise G., Ripamonti G. andTamburini M.: A new method of pain quantification based on a weekly self-description record of the intensity and duration of pain.In:Advances in Pain Research and Therapy. Eds: Bonica J.J., Lindblom U., Iggo A. Vol. 5, Raven Press, New York, p. 891–895, 1983.
Walker V.A., Hoskin P.J., Hanks G.W. andWhite I.D.: Evaluation of WHO analgesic guidelines for cancer pain in a Hospital-based Palliative Care Unit.J. Pain Sympt. Manag. 3, 145–149, 1988.
Walsh T.D. andSaunders C.M.: Oral morphine for relief of chronic pain from cancer.N. Engl. J. Med. 305, 1417, 1981.
World Health Organization.Cancer Pain Relief. WHO: Office of Publication. Genève, 1986.
Author information
Authors and Affiliations
About this article
Cite this article
De Conno, F., Barletta, L., Milani, S. et al. Révision des résultats du traitement antalgique par la morphine orale vis-à-vis de différentes pathologies oncologiques. Doul. et Analg. 3, 55–57 (1990). https://doi.org/10.1007/BF03011369
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03011369